Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Biodesix (BDSX) Net Income towards Common Stockholders: 2019-2024

Historic Net Income towards Common Stockholders for Biodesix (BDSX) over the last 6 years, with Dec 2024 value amounting to -$42.8 million.

  • Biodesix's Net Income towards Common Stockholders rose 14.17% to -$9.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$40.0 million, marking a year-over-year increase of 8.24%. This contributed to the annual value of -$42.8 million for FY2024, which is 15.96% up from last year.
  • Biodesix's Net Income towards Common Stockholders amounted to -$42.8 million in FY2024, which was up 15.96% from -$50.9 million recorded in FY2023.
  • Biodesix's 5-year Net Income towards Common Stockholders high stood at -$30.5 million for FY2020, and its period low was -$58.7 million during FY2022.
  • Its 3-year average for Net Income towards Common Stockholders is -$50.8 million, with a median of -$50.9 million in 2023.
  • Per our database at Business Quant, Biodesix's Net Income towards Common Stockholders plummeted by 48.91% in 2021 and then increased by 15.96% in 2024.
  • Yearly analysis of 5 years shows Biodesix's Net Income towards Common Stockholders stood at -$30.5 million in 2020, then slumped by 48.91% to -$45.4 million in 2021, then dropped by 29.07% to -$58.7 million in 2022, then rose by 13.26% to -$50.9 million in 2023, then increased by 15.96% to -$42.8 million in 2024.